Drugs, money and society.
作者信息
Walley T
机构信息
Department of Pharmacology and Therapeutics, University of Liverpool.
出版信息
Br J Clin Pharmacol. 1995 Apr;39(4):343-5. doi: 10.1111/j.1365-2125.1995.tb04461.x.
Abstract
摘要
相似文献
1
Drugs, money and society.毒品、金钱与社会。
Br J Clin Pharmacol. 1995 Apr;39(4):343-5. doi: 10.1111/j.1365-2125.1995.tb04461.x.
2
Experiments in health care reform.医疗保健改革实验。
Rehab Manag. 1993 Jun-Jul;6(4):173-5.
3
Physicians and health-care reform: rolling up our sleeves or rolling the dice?医生与医疗改革：是挽起袖子实干还是冒险一搏？
Am J Gastroenterol. 2009 Jul;104(7):1617-9. doi: 10.1038/ajg.2009.340.
4
Healthcare in the future era of dynamic change.动态变革的未来时代的医疗保健。
J La State Med Soc. 2003 Jul-Aug;155(4):203-5.
5
Observations regarding the Brown-Johnson debate.
Health Care Manage Rev. 1996 Winter;21(1):61-4.
6
Some personal reflections on health care reform.关于医疗保健改革的一些个人思考。
J Clin Psychopharmacol. 2008 Dec;28(6):599-600. doi: 10.1097/JCP.0b013e31818eec7c.
7
President's page: dollars without the sense.主席致辞：无意义的金钱。
J Am Coll Cardiol. 2002 Feb 6;39(3):540-1. doi: 10.1016/s0735-1097(01)01805-8.
8
A commitment to value, unleashed: hospitals step up.释放对价值的承诺：医院挺身而出。
Hosp Health Netw. 2013 May;87(5):59.
9
Health financing during an economic crisis: Indonesian experiences (July 1997-July 1998).经济危机期间的卫生筹资：印度尼西亚的经验（1997年7月 - 1998年7月）
Cah Sociol Demogr Med. 2000 Jan-Mar;40(1):47-71.
10
A time for reform in health care litigation.医疗保健诉讼改革的时机。
Am J Surg. 2004 Mar;187(3):319-22. doi: 10.1016/j.amjsurg.2003.12.017.
引用本文的文献
1
Drugs, money and society (Part II).毒品、金钱与社会（第二部分）。
Br J Clin Pharmacol. 2010 Sep;70(3):342-5. doi: 10.1111/j.1365-2125.2009.03569.x.
2
From NCE to NICE: the role of pharmacoeconomics.从新化学实体到优质药物：药物经济学的作用
Br J Clin Pharmacol. 2010 Sep;70(3):317-9. doi: 10.1111/j.1365-2125.2010.03708.x.
3
Public views on priority setting for high cost medications in public hospitals in Australia.澳大利亚公众对公立医院高成本药物的优先排序看法。
Health Expect. 2007 Sep;10(3):224-35. doi: 10.1111/j.1369-7625.2007.00439.x.
4
The value of reporting therapeutic ineffectiveness as an adverse drug reaction.
Drug Saf. 2000 Aug;23(2):95-9. doi: 10.2165/00002018-200023020-00001.
5
Cost implications of prehospital emergency drug administration. The case of prehospital thrombolytics.院前急救药物使用的成本影响。以院前溶栓药物为例。
Pharmacoeconomics. 1996 Nov;10(5):441-52. doi: 10.2165/00019053-199610050-00001.
6
Pharmacoeconomics: a challenge for clinical pharmacologists.药物经济学：临床药理学家面临的一项挑战。
Br J Clin Pharmacol. 1995 Sep;40(3):199-202. doi: 10.1111/j.1365-2125.1995.tb05775.x.
本文引用的文献
1
Drug utilisation studies as tools in health economics.药物利用研究作为卫生经济学中的工具。
Pharmacoeconomics. 1994 Apr;5(4):299-312. doi: 10.2165/00019053-199405040-00005.
2
Health economics in primary care in the UK: containment of drug costs.英国初级医疗保健中的卫生经济学：控制药品成本
Pharmacoeconomics. 1993 Feb;3(2):100-6. doi: 10.2165/00019053-199303020-00003.
3
Drug utilisation review and pharmacoeconomics: interaction after parallel development?药物利用评价与药物经济学：平行发展后的相互作用？
Pharmacoeconomics. 1993 Sep;4(3):162-72. doi: 10.2165/00019053-199304030-00002.
4
Is there a need for an independent centre for pharmacoeconomics in the UK?英国是否需要一个独立的药物经济学中心？
Pharmacoeconomics. 1994 Feb;5(2):93-100. doi: 10.2165/00019053-199405020-00003.
5
Clinical pharmacology and therapeutics in undergraduate medical education in the UK: current status.英国本科医学教育中的临床药理学与治疗学：现状
Br J Clin Pharmacol. 1994 Feb;37(2):129-35. doi: 10.1111/j.1365-2125.1994.tb04252.x.
6
Centers for education and research in therapeutics.
Clin Pharmacol Ther. 1994 Mar;55(3):249-55. doi: 10.1038/clpt.1994.24.
7
Research and development for the National Health Service.为国民医疗服务体系开展的研发工作。
Lancet. 1991 Aug 10;338(8763):367-71. doi: 10.1016/0140-6736(91)90494-a.
8
Warning signals from Oregon.来自俄勒冈州的警示信号。
BMJ. 1992 Jun 6;304(6840):1457-8. doi: 10.1136/bmj.304.6840.1457.
Zotero 插件